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bifurcation (>16mm) and IIA (4-9mm). A right IIA
bypass was performed in a ﬁrst stage via small ﬂank incision.
For the second stage, EVAR was performed using bilateral
percutaneous femoral approach. After systemic hepariniza-
tion, a 12Fr Ansel sheath (Cook Inc., Bloomington IN)
was introduced via the right and IBD via the left femoral
approach. A guidewire was advanced via the IBD pre-
loaded catheter and snared, establishing femoral-femoral
access. The IBD was partially deployed up to the side
branch, which was opened 1-cm proximal to the CIA bifur-
cation. The 12 Fr sheath was advanced into the side
branch, followed by selective catheterization the IIA and
deployment of a 9  60 mm self-expandable stent-graft
into the IIA. The IBD was deployed into the left external
iliac artery (EIA) and kissing balloon angioplasty was per-
formed. The repair was completed by deployment of
a Cook Zenith (Bloomington IN) bifurcated stent-graft
and iliac limb extensions to connect the IBD to the left
contra-lateral gate and extend the repair to the right EIA.
Completion angiography and CTA revealed widely patency
stent-grafts with no endoleak. In conclusion, IBDs have
expanded the indications of EVAR in patients with bilateral
CIA aneurysms. The technique can be performed using
a total percutaneous approach and has the potential to
reduce rates of pelvic ischemic complications.
Author Disclosures: M. P. Correa: Nothing to disclose;
G. S. Oderich: Cook Medical, Inc, Research Grants
W.L. Gore, Research Grants.AneuRx 25
Excluder 25
Zenith 17
Talent 15
Ancure 10
Powerlink 4
Endurant 1
Quantum LP 1
Uni Iliac Rupture Graft 1
Home Made 1SS8.
The First 100 Late EVAR Explants: Largest Single
Center Experience
Eric J. Turney, Sean Steenberge, Sean Lyden, Matthew
Eagleton, Sunita Srivastava, Timur Sarac, Rebecca Kelso,
Daniel Clair. Vascular Surgery, Cleveland Clinic,
Cleveland, Ohio
Objectives: With over a decade of use of endovascular
aneurysm repair (EVAR) we have seen a rise in the number
of failing endografts. In 2007 we previously reported 41
explants and sought to re-examine our outcomes.
Methods: A retrospective analysis of EVARs requiring
late explant was performed using a database. The type of
graft, duration of implant, reason for removal, operative
technique, mortality and length of stay were reviewed.
Results: During 1999-2012, 100 patients required
explant, of which 60 were placed at an outside institution
(Table). Twenty-seven were performed in the last two years.
Ninety-one were male with an average age of 75 years
(range, 50-93 years). Grafts were excised after a median of
41 months (range, 1-144 months). Average length of stay
was 15 days (range, 1-56 days). 30 day mortality was 17%.
Elective mortality was 9.9%. There was no difference in
approach (56 retroperitoneal, 44 midline). 82% patients
had one or more endoleaks (type I, 40; II, 30; III, 22; endo-
tension, six). Migration (15), rupture (nine), aortoenteric
ﬁstula (ﬁve), infection (13), limb thrombosis (three) and
claudication (one) were also factors. Repairs were 18 tube,
66 aortoiliac, eight aorto-femoral, and seven axillo-femoral.
Twenty-two patients had partial graft excision.Conclusions: An increasing number of endografts are
being referred for removal. The overall mortality is slightly
improved to 17% from 19% in our original series despite
increased elective mortality to 9.9% from 3.3%.
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COL3A1GeneMutation Predicts Arterial Involvement
and Prognosis in Vascular Ehlers Danlos Syndrome
Sherene Shalhub1, Nazli McDonnel2, Alana C. Cecchi1, Ali
Azizzadeh1, Kristofer M. Charlton-Ouw1, James Black3,
Reed Pyeritz4, Anthony L. Estrera1, Hazim Saﬁ1, Dianna
Milewicz1. 1Department of Cardiothoracic & Vascular
Surgery, The University of Texas Medical School at
Houston, Houston, Tex; 2National Institute on Aging,
National Institute of Health, Baltimore, Md; 3Johns
Hopkins Hospital, Baltimore, Md; 4University of
Pennsylvania School of Medicine, Philadelphia, Pa
Objectives: Patients with vascular Ehlers-Danlos syn-
drome (vEDS) often present with spontaneous arterial
dissection or rupture. Mutations in the COL3A1 gene
that encodes type III collagen include missense mutations
(MIS) and haploinsufﬁciency (HI) mutations. The aim is
to describe the outcomes of vEDS patients based on
genotype.
Table. 30-day MACE by procedure
Primary outcome Women Men P value
All CEA 4.09% (110/2689) 4.05% (155/3829) .9492
All CAS 7.18% (108/1504) 6.88% (158/2297) .7453
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nosis of vEDS presenting at two tertiary referral centers
from 2000 to 2012 were reviewed. Data collected
included demographics, family history, vascular pathology,
operative details, and outcomes. To replicate the pheno-
type-genotype correlation a second cohort was reviewed
using data from the Genetically Triggered Thoracic Aortic
Aneurysms and Cardiovascular Conditions Registry (Gen-
TAC), a National Institutes of Health-funded multicenter
database.
Results: A total of 62 cases (34% male, 75% with
positive family history, 15% HI) were identiﬁed. Arterial
aneurysms and dissections were seen in 38 (62%) cases.
Median age at initial vascular presentation was 41 (range
39-58) years in the HI group vs 33 (range 17-68) years in
MIS group. Aortic and mesenteric arterial involvement
was more common in the HI than MIS group (44% vs
15% and 44% vs 23%, respectively). The mortality was
0% in the HI group and 17% in the MIS group. The Gen-
TAC registry enrolled 103 cases (29% male, 55% with
positive family history, 6% HI). Median age at diagnosis
was 28 (range 1-63) years. Once again, aortic involve-
ment was more common in the HI vs MIS group (50%
vs 10%).
Conclusions: Aortic and mesenteric arterial involve-
ment in vEDS appears to be related to the underlying
mutation type, with the HI cases having milder disease
and later presentation. Molecular diagnosis is warranted
in vEDS cases as it predicts postoperative outcomes and
guides surveillance.
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hub: Nothing to disclose.Symptomatic CEA 5.91% (57/964) 5.39% (81/1502) .5910
Symptomatic CAS 8.31% (56/674) 9.47% (101/1067) .4402
Asymptomatic CEA 3.07% (53/1725) 3.18% (74/2327) .9274
Asymptomatic CAS 6.27% (52/830) 4.63% (57/1230) .1092
All Symptomatic 6.90% (113/1638) 7.08% (182/2569) .8527
All Asymptomatic 4.11% (105/2555) 3.68% (131/3557) .4194S3: SVS Plenary Session III
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GenderDifferences After Carotid Endarterectomy (CEA)
and Carotid Artery Stenting (CAS) in the Society for
Vascular Surgery Vascular Registry (SVS-VR)
Jeffrey Jim1, Ellen D. Dillavou2, Gilbert R. Upchurch3,
Nicholas H. Osborne4, Christopher T. Kenwood5, Flora
S. Siami5, Rodney A. White6, Joseph J. Ricotta7.
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Arbor, Mich; 5New England Research Institutes, Inc,
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Objectives: While optimal treatment of carotid
stenosis remains unclear, available data suggest that women
have higher risk of adverse events after carotid revasculari-
zation. SVS-VR data was used to determine the impact of
gender after CEA and CAS.
Methods: 10,319 patients (41% women) underwent
CEA (6518) and CAS (3801). The primary end pointwas a composite of death, stroke and myocardial infarction
(MACE) at 30-days. The effect of symptom status and
gender on outcomes was also analyzed.
Results: There was no difference in age between
genders, but men were more likely to be symptomatic
(41% v 39%). Women were more likely to have hyperten-
sion and COPD while men had a higher prevalence of
CAD and smoking history. For disease etiology in CAS,
restenosis was more common in women (28% v 21%)
while radiation was higher in men (7% vs 3%). MACE
was lower for CEA in all patient groups in both genders
(P < .05 for all comparisons between CEA and CAS).
Comparing women and men (Table), there were no
statistically signiﬁcant differences in MACE for either
CEA (4% vs 4%) or CAS (7% vs 7%), which remained
even after stratiﬁcation by symptomatology and multivar-
iate risk adjustment.
Conclusions: In this large, real-world analysis, women
and men demonstrated similar results after CEA or CAS.
These data suggest that, contrary to previous reports,
women derive similar beneﬁts as men from carotid revascu-
larization. However, CAS is associated with inferior
outcomes compared to CEA for both women and men,
regardless of symptom status.
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Ischemic Events and Stroke: Results From the
ACSRS Study
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Objectives: To determine the association between
progression of internal carotid artery stenosis and subse-
quent ipsilateral cerebral ischemic events (AF, TIA or
stroke) in the Asymptomatic Carotid Stenosis and Risk of
Stroke (ACSRS) Study.
Methods: 1121 patients with asymptomatic carotid
stenosis 50-99% in relation to the bulb diameter were
followed-up 6-monthly clinically and with carotid duplex
